INTERNATIONAL PATENT: SERMONIX PHARMACEUTICALS, INC., THE REGENTS OF THE UNIVERSITY OF CALIFORNIA FILES APPLICATION FOR "NEOADJUVANT TREATMENT OF ER+ BREAST CANCER WITH LASOFOXIFENE"

GENEVA, May 12 -- SERMONIX PHARMACEUTICALS, INC. (250 East Broad Street, Suite 250Columbus, OH 43215), THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (1111 Franklin Street, Twelfth FloorOakland, CA 94607-5200) filed a patent application (PCT/US2025/053415) for "NEOADJUVANT TREATMENT OF ER+ BREAST CANCER WITH LASOFOXIFENE" on Oct 30, 2025. With publication no. WO/2026/096820, the details related to the patent application was published on May 07, 2026.

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Inventor(s): PORTMAN, David, J. (c/o Sermonix Pharmaceuticals, Inc.250 East Broad Street, Suite 250Columbus, OH 43215...